To access this element change to forms mode OFF
Grant Award View - GA187368
Novel SMART AAV vectors for gene therapy for Friedreich's Ataxia
GA ID:
GA187368
Agency:
Department of Health and Aged Care
Approval Date:
11-Jun-2021
Publish Date:
30-Aug-2021
Category:
Health and Medical Research
Grant Term:
11-Jun-2021 to 31-May-2024
Value (AUD):
$982,861.60
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 20/21 1.1 Health Policy Research and Analysis
Grant Program:
2020_MRFF_Stem_Cell_Therapies_Mission
Grant Activity:
Novel SMART AAV vectors for gene therapy for Friedreich's Ataxia
Purpose:
Friedreich's ataxia (FRDA) is an inherited disease caused by mutations in Frataxin gene leading to a significant loss of Frataxin protein levels in the body. Reduced Frataxin levels leads to cell degeneration, particularly within heart tissue and the nervous system. Gene therapy is currently at the forefront as a potential approach to successfully treat FRDA. This proposal will use human stem cells as a platform to significantly advance current technologies in gene therapy to treat FRDA.
GO ID:
GO Title:
MRFF – Stem Cell Therapies Mission – 2020 Stem Cell Therapies Grant Opportunity
Internal Reference ID:
MRF2007421
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Wollongong
Recipient ABN:
61 060 567 686
Grant Recipient Location
Suburb:
Wollongong
Town/City:
Wollongong
Postcode:
2500
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, QLD
Postcode:
Multiple
Country:
AUSTRALIA